AlloVir to Present at the 39thAnnual J.P. Morgan Healthcare Conference
AlloVir to Present at the 39thAnnual J.P. Morgan Healthcare Conference
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39thAnnual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.
An audio-only webcast of the presentation will be available on January 11thon the Investors & Press section of the AlloVir website at https://ir.allovir.com . An archived replay of the presentation will be available for approximately 30 days following the presentation.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com .
AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39thAnnual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.
AllVir,Inc.。临床晚期细胞治疗公司(纳斯达克股票代码:ALVR)将于2021年1月11日上午9点10分在第39届摩根大通医疗年会上介绍公司概况。Et.
An audio-only webcast of the presentation will be available on January 11thon the Investors & Press section of the AlloVir website at https://ir.allovir.com . An archived replay of the presentation will be available for approximately 30 days following the presentation.
演讲的纯音频网络直播将于1月11日在阿洛维尔公司网站的投资者和媒体部分播出,网址是:https://ir.allovir.com。演示文稿的存档回放将在演示结束后大约30天内提供。
About AlloVir
关于AllVir
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com .
阿洛维尔是一家领先的临床晚期细胞治疗公司,专注于恢复免疫系统减弱患者对危及生命的病毒疾病的自然免疫力。该公司的创新和专有技术平台利用现成的同种异体多病毒特异性T细胞,针对T细胞缺陷患者的破坏性病毒,这些患者面临病毒疾病危及生命的后果。阿洛维尔公司的技术和制造工艺使治疗和预防每一种单一的同种异体细胞疗法的破坏性病毒谱成为可能。该公司正在推进其产品组合中的多项中后期临床试验。欲了解更多信息,请访问www.allovir.com。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧